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Acute leukemiaAbstract Background: Angiogenesis is a fundamental element during malignant transformation,
the induction of angiogenesis has been proposed to be through angiogenic factors such as the
hepatocyte growth factor (HGF).
Aim: The aim of the study was to assess plasma concentrations of HGF in acute leukemia in Upper
Egypt.
Methods: We performed a cross-sectional study of 90 subjects and divided them into three groups,
group I consisted of 30 newly diagnosed acute lymphatic leukemia (ALL) cases, group II consisted
of 30 patients with newly diagnosed acute myeloid leukemia (AML) cases and group III consisted of
30 apparently healthy persons as control subjects. Plasma HGF was measured using the ELISA
technique.
Results: Statistical comparison between the mean values of plasma HGF in the three studied
groups using the F-test followed by the least signiﬁcant difference showed a signiﬁcant difference
(F= 77, P= 0.001) between ALL cases and the control group and between AML cases and the
control group.
Conclusion: The results of the present study suggest that high plasma HGF may play a signiﬁcant
role in the leukemia process and contribute to the leukemic cell dissemination. The clinical
signiﬁcance of the increased level of HGF in acute leukemia needs further investigation and may
suggest a novel therapeutic approach in this disease.
Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric Association. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Acute leukemia is a heterogeneous group of malignant disor-
ders arising from the hematopoietic progenitor cell at different
stages of maturation. It is characterized by the appearance of
immature cells (blasts) in the bone marrow cells, resulting in
anemia, thrombocytopenia and an outpouring of the neoplas-
tic blasts into the peripheral blood. They may inﬁltrate other
Plasma concentrations of HGF in acute leukemia 13parenchymatous organs such as the liver, spleen and lymph
nodes. The blasts have common characteristics which include
rapid proliferation, immaturity and poor responsiveness to
regulatory mechanisms.1,2 There are two types of leukemia:
Acute lymphoblastic Leukemia (All) and Acute myeloid leuke-
mia (AML). All is a proliferation of lymphoblasts originating
in lymphocyte progenitor cells of the bone marrow2 while
AML originates from myeloid hematopoeitic cells which
include myeloblasts, monoblasts, erythroid precursors and
megakaryoblasts.3
Acute myeloid leukemia is a relatively rare cancer. There
are approximately 10,500 new cases each year in the United
States, and the incidence rate has remained stable from 1995
through 2005. AML accounts for 1.2% of all cancer deaths
in the United States.4
The incidence of AML increases with age; the median age
at diagnosis is 63 years. AML accounts for about 90% of all
acute leukemia in adults, but is rare in children.1 The rate of
therapy-related AML (that is, AML caused by previous che-
motherapy) is rising; therapy-related disease currently
accounts for about 10–20% of all cases of AML. AML is
slightly more common in men, with a male-to-female ratio of
1.3:1.5
There are many risk factors for acute leukemias; I- Envi-
ronmental Factors: Three well documented environmental fac-
tors are established causal agents increasing the risk of AML;
exposure to high dose of external radiation, chronic benzene
exposure and chemotherapeutic agents as alkylating agents,5
while pesticide exposure (occupational or home use) and par-
ental cigarette smoking before or during pregnancy have been
suggested as causes of childhood ALL. Other proposed causes
of childhood ALL include neonatal administration of vitamin
K and maternal alcohol consumption during pregnancy.6 II-
Acquired disease (Evolution from a chronic clonal hemopa-
thy); AML may develop from progression of other clonal dis-
orders of hematopoietic stem cells including chronic myeloid
leukemia CML, polycythemia vera, idiopathic myeloﬁbrosis
and primary thrombocythemia.7 III- Inherited conditions;
Down’s syndrome: children with down’s syndrome have a
10–30-fold increased risk of leukemia AML predominates in
patients younger than 3 years and ALL in the older age
group,8 Fanconi syndrome9 and Bloom syndrome.9
The term angiogenesis, ﬁrst used by Hertig in 1935 to
describe the growth of blood vessels in the placenta, was re-in-
troduced by Folkman in 1972 to describe neovascularization
accompanying solid tumor growth.10 Angiogenesis is the
process by which new capillaries sprout and differentiate from
pre existing blood vessels. This process results in newly
developed microvessels, most of which resemble capillaries
(diameter of 5–8 lm). This process is distinct from vasculoge-
nesis, which occurs during embryonic development and
involves the formation of larger blood vessels from stem cells
of mesenchymal origin called angioblasts.11 In normal mature
adults, angiogenesis is a rare event that occurs only in certain
specialized situations such as during the female reproductive
and menstrual cycle. Micro vascular blood vessels are
extremely long lived. The endothelial cells that line the
microvasculature have a half-life of months to years.12
Abnormal or pathologic angiogenesis can be seen in diseases
such as rheumatoid arthritis, diabetic retinopathy, infantile
hemangiomas, psoriasis and cancer.11 Hepatocyte growth
factor/scatter factor was initially identiﬁed in 198413 andmolecularly cloned as a potent mitogen of primary cultured
hepatocytes.14 It has multiple activities (multifunctional cyto-
kine) in a variety of tissues during the course of development
and also in various disease states. It is named scatter factor
as it affects the increase in local motility and a scattering of
contiguous sheets of cells. This factor might be involved in
epithelial migration such as that which occurs in embryoge-
nesis and wound healing.15 Molecular cloning revealed that
HGF is a heterodimeric molecule composed of a 69 kDa a
chain and 34 kDa b chain. The a chain contains an N-terminal
hairpin domain and subsequent four-kringle domains. The b
chain contains a serine protease like domain with no enzymatic
activity.16 The a subunit and the b subunit have a length of 440
and 234 amino acids respectively.17 HGF is synthesized and
secreted as a biologically inactive single chain precursor form,
and further processing by the Serine protease into the two
chain form. Serine proteases responsible for the activation of
HGF include HGF activator or HGF converting enzyme
and urokinase type plasminogen activator (UPA).18 The recep-
tor for HGF was identiﬁed as c-Met proto-oncogene product.
The c-Met receptor is composed of a 50 kDa a chain and
145 kDa b-chain. The a chain is exposed extracellularly, while
the b-chain is a transmembrane subunit containing an intracel-
lular tyrosine kinase domain.19 Binding of HGF to the c-Met
receptor induces activation of tyrosine kinase, an event that
results in subsequent phosphorylation of c-terminally cultured
tyrosine residues. Although HGF was initially identiﬁed as a
potent mitogen for hepatocytes, considerable evidence indi-
cates that intracellular signaling pathways driven by HGF
and c-Met receptor coupling leading to multiple biological
responses in a variety of cells including mitogenic, motogenic
(enhancement of cell motility), morphogenic, neurite exten-
sion, anti-apoptotic activity and enhancement of hematopoi-
esis. HGF has also an organotrophic role in the regeneration
and protection of various organs including the liver, lung,
stomach, pancreas, heart, brain and kidney. Cells shown to
express HGF mRNA include megakaryocytes, monocytes, pla-
telets, ﬁbroblasts, smooth muscle cells, mast cells and endothe-
lial cells but not epithelial cells. Various types of human
leukemia cells also secrete HGF. Expression of HGF receptor
in vitro and in vivo in epithelial cells suggests that HGF acts in
a paracrine fashion to mediate interactions between epithelial
and stromal cells during development and in normal tissue
maintenance.19,20 HGF is a potent inducer of angiogenesis, a
process necessary for the continued growth of tumors. In vitro,
HGF stimulates endothelial cell proliferation, chemotaxis and
chemokinesis, it promotes migration of endothelial cell from
carrier beads to ﬂat surfaces and it induces capillary like tube
formation. It has also been reported that HGF induces
endothelial cell expression of plasminogen activators. In vivo
studies also indicated that HGF induced neovascularization
exceeds that achieved with VEGF. HGF has been shown to
be induced in Skeletal muscle after ischemic injury and it has
been implicated in capillary endothelial cell regeneration in
ischemically injured myocardium. The receptor for HGF the
c-Met proto-oncogene product is expressed by endothelial cells
and pericytes of blood vessel walls, because HGF is apparently
produced by stromal cells located outside the vessel wall, it has
been suggested that it may act as a paracrine mediator in the
angiogenic cascade.20,21
Bone marrow stromal cells which include macrophages,
ﬁbroblasts, endothelial cells, and adipocytes have been shown
14 A.E. Ahmed et al.to produce several factors that modulate the growth of bone
marrow progenitors as HGF which is ﬁbroblast derived. Bone
marrow cells were found to express both c-Met m RNA and its
protein, also c-Met m RNA has been detected in several
murine hematopoietic progenitor cell lines, suggesting that
HGF and c-Met might function during hematopoiesis. HGF
was shown to synergize with interleukin-3 (IL-3) and granulo-
cyte macrophage colony stimulating factor to stimulate colony
formation of hematopoietic progenitor cells. In vitro HGF
may be a regulatory protein for the proliferation and differen-
tiation of hematopoietic progenitors and is considered as a
new member of the functionally related group of factors that
modulate hematopoiesis.22 HGF expression was detected in
various types of leukemia/lymphoma cell lines particularly in
plasma cell and myeloid malignancies.23 It has a mitogenic
activity on myeloid leukemia cell lines. High level of HGF is
found in the blood and bone marrow plasma from patients
with various types of leukemia.24
The aim of this study
To estimate of the plasma concentration of HGF as an angio-
genic factor in acute leukemia.
Study design and methodology
This study included three groups: three groups, group I con-
sisted of 30, newly diagnosed ALL cases, group II consisted
of 30 patients with newly diagnosed AML cases and group
III consisted of 30 apparently healthy persons as control sub-
jects. The patients were selected from the main hospital of the
South Valley University. All subjects were subjected to the fol-
lowing; thorough history taking and clinical examination with
special stress on the presence of extramedullary inﬁltration
such as gum hypertrophy, lymphadenopathy, hepatomegally,
CNS involvement and skin inﬁltration, complete blood count,
bone marrow examination (For patients), Liver and kidney
function tests, radiological study: X-ray chest and abdominal
ultrasound. Five milliliters of the venous blood was collected
into a disposable tube containing ethylene diamine tetra acetic
acid (EDTA) 5% as an anticoagulant, centrifugation was done
immediately after centrifuging at 1000g for 10 min and the
recovered plasma was stored at 70 C till the time of assay
of HGF. Estimation of plasma concentration of HGF was
done by the ELISA technique.25 The kit was supplied by R
and D systems, Inc. 614 Mc Kinky place N.E. Minneapolis.
MN 55413 United States of America.
Patients with ALL were treated with a combination of
intravenous push of daunorubicin 50 mg/m2 for the ﬁrst 3 days
of therapy, 2 mg intravenous bolus of vincristine at days 1, 8,
15 and 22 and prednisone 60 mg/m2 daily for 28 days. They
were considered in complete remission when they had <5%
blasts in a cellular bone marrow recovery of peripheral
neutrophils and platelets and the absence of detectable
extramedullary leukemia.26
AML patients were treated by 7 and 3 regimens. AML
patients were considered in complete remission (CR) when
they have a morphological normal bone marrow containing
<5% blasts and no Auer rods, absence of extramedullary leu-
kemia, and normalization of neutrophil counts (at least
1.5 · 109/L) and platelet counts (>100 · 109/L). These criteriashould be maintained for at least 4 weeks or until the initiation
of intensiﬁcation therapy. Partial remission (PR) was deﬁned
by 5–25% bone marrow blasts.27 All patients were followed
for response to chemotherapy for at least 6 monthsEthical considerations
The study was approved by the Researches and Ethics Review
Committee at the Qena Faculty of Medicine, South Valley
University. A written consent was obtained from the parents
or patients, guardians upon enrollment to the study after a
detailed explanation of the study objectives, interventions
and possible beneﬁts of participants.Statistical analysis
The study data were statistically analyzed using the Statistical
Package for Social version program (SPSS program-version
10.0 – SPSS Inc., Chicago, IL, USA). The differences between
cases and control as regards quantitative variables were
calculated using an ANOVA, F test and Kruskal–Wallis. For
testing association between categorized variables chi square
and Monte Carlo were used. Pearson’s correlation test was
done to study the possible correlation between quantitative
variables. Statistical signiﬁcance was assessed at P< 0.05.
All calculated P values were two-tailed.
Results
The study was conducted on 60 patients suffering from
acute leukemias. 30 cases were ALL{(4)L1,(12)L2,(14)L3}
18 of them were males. 30 cases were AML{(8) M1,(4)
M2,(4) M3,(4) M4,(6) M5,(2) M6,(2), M7} 12 of them were
males. The cases were matched in respect to their ages
and sex with 30 controls. 14 males and 16 females. Among
ALL cases, 26 cases (86.7%) presented with pallor while
among AML cases 24 cases (80%) presented with pallor.
However the difference between the two groups was not
statistically signiﬁcant (X2 = 0.000, P> 0.05). 20 cases
(66.7%) of ALL and AML cases presented with hemorrhage
and the difference between the two groups was not
statistically signiﬁcant (X2 = 0.000, P> 0.05).
In ALL cases, 20 cases (66.7%) presented with fever while
in AML cases 6 cases (20%) presented with fever and this was
statistically signiﬁcant (X2 = 6.652, P< 0.05). In ALL cases 2
patients (6.7%) presented with hepatosplenomegaly, 8 patients
(26.7%) with lymphadenopathy, 12 patients (40%) with
hepatosplenomegaly plus lymphadenopathy.
In AML cases, 10 patients (33.3%) presented with
hepatosplenomegaly, 2 patients (6.7%) with hepatosplenomegaly
plus lymphadenopathy, 4 patients (13.3%) with hep-
atosplenomegaly plus gum hypertrophy, 4 patients (13.3%)
with splenomegaly and this was statistically signiﬁcant Monte
Carlo P> 0.000.
In ALL cases 22 cases (73.3%) entered into remission, 4
patients (13.3%) entered into partial remission while 4 patients
(13.3%) died. In the AML case, 14 cases (46.7%) were in
remission, 2 cases (6.7%) were in partial remission, 8 cases
(26.7%) were resistant to therapy and 6 cases (20%) died
and this was not statistically signiﬁcant (P> 0.05).
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Figure 1 Mean levels of HGF in ALL, AML and the control
group.
Plasma concentrations of HGF in acute leukemia 15Hematological data
In ALL cases, Hb values ranged from (3 to 9.5 g/dl) with
X SD of (6.506 ± 1.931 g/dl), while in AML cases Hb values
ranged from (3.5 to 12 g/dl) with X SD (7.72 ± 2.275 g/dl).
In the control group Hb values ranged from (12.7 to 14.5
g/dl) with X SD (13.68 ± 0.578 g/dl). There was a signiﬁcant
difference between ALL, AML and control groups,
F= 71.796, P 6 0.000). This difference using LSD was
signiﬁcant between ALL cases and controls and AML cases
and the control group.
InALL cases, RBC counts ranged from (0.94 ± 3.5 · 1012/L)
with X SD (2.398 ± 0.762 · 1012/L). In AML cases, the RBC
ranged from (1–4.1 · 1012/L) with X SD (2.793 ±
0.859 · 1012/L) while in the control group, it ranged from 4.39
to 4.84 · 1012/L with X SD (4.642 ± 0.187 · 1012/L). There
was a signiﬁcant difference between ALL, AML and control
groups F= 52.027, P 6 0.000 and this difference using LSD
was signiﬁcant between ALL cases and control and AML cases
and controls.
In ALL cases WBC counts ranged from (5.1 to 200 · 109/L)
withX SD (40.16 ± 55.141 · 109/L). InAML cases, it ranged
from (2 to 92.5 · 109/L) with X SD (22.08 ± 25.81 · 109/L)
while in the control group, it ranged from (4.2 to 6.7 · 109/L)
with X SD (5.281 ± 0.791 · 109/L) and this was statistically
signiﬁcant between ALL cases and the control group and
AML cases and the control group.
In ALL cases the platelets ranged from (12 to 130 · 109/L)
with X SD (72.033 ± 67.127 · 109/L). In AML cases, it ran-
ged from (15 to 138 · 109/L) with X SD (61.2 ±
41.167 · 109/L) while in the control group, it ranged from (220
to 332 · 109/L) with X SD (254.467 ± 28.65 · 109/L). There
was a signiﬁcant difference between ALL, AML and control
group F= 75.57, P= 0.000. Using the LSD the differenceTable 1 Comparison between the three studied groups as regards h
Parameter ALL (n= 30) AML (n= 30)
Hb (g/dl)
Range 3–9.5 2.5–12
X SD 6.506 ± 1.931 7.72 ± 2.275
RBC (·1012/L)
Range 0.94–3.5 1–4.1
X SD 2.398 ± 0.7629 2.593 ± 0.859
WBC (·109/L)
Range 5.1–200 2–92.5
X SD 40.16 ± 55.141 22.08 ± 25.81
Platelets (·109/L)
Range 12–130 15.138
X SD 72.033 ± 60.127 61.2 ± 41.167
PB blast (%)
Range 20–85 5–80
X SD 56.2 ± 20.73 46.333 ± 24.025
BM blast (%)
Range 60–93 32–93
X SD 83.2 ± 11.194 62.066 ± 21.819
P= probability of signiﬁcance, signiﬁcant 60.05, Highly signiﬁcant 60.0was signiﬁcant between ALL cases and controls and between
AML cases and controls.
The peripheral blood blasts (PB blast) ranged from (20% to
85%) in ALL cases with X SD (56.2 ± 20.73%) while it ran-
ged from (5% to 80%) in AML cases with X SD (46.333 ±
24.025%) and this was not signiﬁcant t= 0.699, P= 0.506.
The bone marrow blasts (BM blast) ranged from (60% to
93%) in ALL cases withX SD (83.2 ± 11.194%) while it ran-
ged from (60% to 93%) the X SD was (62.066 ± 21.819%)
and this was not signiﬁcant between the two groups (t= 5.37,
P= 0.07) (Table 1).
Results of HGF as regards the extra-medullary inﬁltration:-
HGF was signiﬁcantly higher in patients presented by
hepatosplenomegaly plus gum hypertrophy (4 patients) with
a mean value of 5.5 ± 1.1 pg/ml followed by 2 patients pre-
sented by hepatosplenomegaly plus lymphadenopathy
(2.03 pg/ml), followed by those presented by splenomegaly (4ematological data.
Controls (n= 30) Test of signiﬁcance P value
F= 71.796
12.7–14.5 P 6 0.000
13.68 ± 0.578 LSD (1,3)* (2,3)*
F= 52.027
4.39–4.84 P 6 0.000
4.642 ± 0.167 LSD (1,3)* (2,3)*
Kruskal–Wallis x2 = 17.5
4.2–6.7 P 6 0.000
5.281 ± 0.791 LSD (1,3)* (2,3)*
F= 75.591
220.332 P 6 0.000
254.667 ± 28.65 LSD (1,3)* (2,3)*
t= 0.699
P= 0.506
t= 5.371
P= 0.111
01* signiﬁcant, X=Mean, SD= standard deviation.
Table 2 Statistical comparison between ALL, AML and control group as regards HGF.
Parameter ALL (n= 30) AML (n= 30) Controls (n= 30) Test of signiﬁcance P value
HGF (pg/ml) F= 7.7
Range 0.68–6.49 0.88–6.35 0.25–0.87 P= 0.001
X SD 2.1 ± 1.6 2.27 ± 1.6 0.4666 ± 0.1 LSD (1,3)* (2,3)*
P= probability of signiﬁcance, signiﬁcant 60.05, highly signiﬁcant 60.001* signiﬁcant, X=Mean, SD= standard deviation.
16 A.E. Ahmed et al.patients) with a mean value of 1.68 ± 0.85 followed by those
presented by hepatosplenomegaly (10 patients) with a mean
value of 1.6 ± 1.13 followed by those patients with no
extramedullary inﬁltration (8 patients) with a mean value of
1.8 ± 1.07 ng/ml (F= 5.05, P= 0.017). As regards the
response to therapy, in ALL and AML cases there was no
signiﬁcant relation between the HGF plasma levels and the
response to therapy (F= 0.941, P= 0.417).
The results of the correlation between plasma levels of
HGF versus the age and hematological parameters in ALL
and AML cases:- There was no signiﬁcant correlation between
plasma levels of HGF versus the age and hematological para-
meters in ALL cases. In AML cases; it is found that HGF
positively correlated with Hb values (r= 0.569, P= 0.027),
RBC counts (r= 0.556, P= 0.032) and WBC counts
(r= 0.936, P= 0.000) (Fig. 1, Table 2).
There was neither signiﬁcant correlation between the
studied angiogenic and apoptotic factors neither with the
hematological parameter nor with the age.
Discussion
Acute leukemia is a malignant disease which is characterized
by three different features, hematopoietic cells arrest at a
certain level of differentiation, progenitor cell continue to
proliferate in a way that displaces normal hematopoiesis and
immature cells prematurely leave the bone marrow to reach
peripheral tissues.28
It is well known that the growth of the solid tumor is angio-
genic dependant. However, the role of angiogenesis in the
growth and survival of leukemias and other hematological
malignancies has been clariﬁed since 1994 in a series of demon-
strations showing that the progression of several leukemias is
tightly related to their degree of angiogenesis.28 This evidence
was reported in patients with acute leukemia in which the
increased angiogenesis disappeared in complete hematological
remission.29
Recently it has been reported that there is an intimate cor-
relation between the increased vessel density found in AML
and (VEGF) expression,30 which is a main angiogenic factor,
therefore it is of interest to investigate the role of other
angiogenic factors like HGF in acute leukemia.
HGF is known as a powerful angiogenic factor and is
believed to increase angiogenesis in a multistep process includ-
ing an effect on the proliferation, motility, adhesion of
endothelial cells and the morphogenesis of new blood vessels.19
Our data proved that the plasma concentration of HGF
was signiﬁcantly higher in ALL and AML patients than in
the control group.
This ﬁnding was in agreement with other studies,31–36 sug-
gesting that the source of elevated HGF to be from blast cells
as it is demonstrated that a variety of human leukemia celllines in culture produce a signiﬁcant amount of HGF which
include T,B, myeloid and erythroid cell lines. Also a high level
of HGF was detected in the blood and bone marrow plasma of
leukemia patients.33
In support of this hypothesis, the eradication of leukemic
blast cells by successful treatment was observed to be accom-
panied by a signiﬁcant diminution of the HGF level in the
bone marrow.31 On the other hand other workers suggested
that the source of HGF may be stromal cells, endothelial cells
and other cells.37
This HGF which is originated from blast cells was suggest-
ed to promote the growth of leukemic blast cells. Isolated
AML blast over expresses HGF and HGF receptors. Thus
the HGF/HGFR pathways can promote the growth of
leukemic blasts in an autocrine and paracrine manner.38
HGF is considered a very aggressive factor as it helps the
formation of extra medullary inﬁltrate and affects patient sur-
vival. The ﬁrst effect was veriﬁed in our study as it has been
revealed that there is a signiﬁcant increase of HGF in AML
cases with extramedullary inﬁltrate compared to patients with-
out. This is matched well with the result of Aref et al.36 who
found HGF was signiﬁcantly elevated in AML patients with
the extramedullary inﬁltrate as compared to those without.
This could be explained according to Fiedler et al.39 who stated
that paracrine stimulation which may not only be restricted to
the bone marrow microenvironment but may also take place at
extramedullary sites. Circulating AML blast may proﬁt from
paracrine provision of growth factors in various capillary beds,
this may result in their expansion in peripheral blood under
favorable conditions. So extramedullary manifestations of
AML such as gingival hyperplasia or organ inﬁltration may
be initiated by a similar mechanism.39
As regards the second effect of HGF on patient’s survival,
it has been found in our study that there was a non signiﬁcant
increase in the mean level of HGF in AML patients who died
than those in patients survived and entered in complete
remission.
In agreement with our results Kim et al.31 found that the
plasma HGF level was increased in AML patients and is con-
sidered as a strongly predictive parameter for complete remis-
sion. Furthermore he stated that AML patients with lower
HGF tended to have better leukemia free survival than those
with higher levels.
An explanation to the observed association between high
HGF and a signiﬁcant lower survival in newly diagnosed
AML patients may be due to augmentation of angiogenesis
induced by cytokines and other angiogenic factors.40 HGF
may exert a potent combination of direct and indirect effects,
including a direct effect on endothelial cells and an indirect
effect via an increase in the production of VEGF.21 In contrast
Hjorth Hansen et al.34 reported no signiﬁcant correlation
between the HGF level in AML patients and the patient
Plasma concentrations of HGF in acute leukemia 17survival. This controversy attributed to the employment of
serum rather than plasma samples, Sakon et al.41 compared
the measurement of HGF in serum and plasma samples and
concluded that HGF plasma levels yield more valid and precise
measurement than HGF serum levels. Blood clotting induces
the release of angiogenic factors from platelets into the serum
during serum isolation.41 In addition, HGF was initially isolat-
ed from normal rat platelets and removal of platelets greatly
reduced the HGF activity of normal rat serum.42
In AML patients HGF of this study was directly correlated
to peripheral total WBCs counts but inversely correlated to Hb
and RBCs counts. This ﬁnding suggests that HGF is an angio-
genic factor correlated with tumor cell mass.31
This ﬁnding was in agreement with other investiga-
tors,31,34,35 who reported that HGF levels in AML were corre-
lated signiﬁcantly with WBCs and monocytic count. HGF
promotes proliferation and migration of blood mononuclear
cells in patients with AML with elevated blasts and it was
found that a neutralizing antibody directed against HGF
reduced AML blast migration signiﬁcantly.23,43
Given these observations HGF could be used as a marker
for disease activity in acute leukemia cases and may add to
the risk stratiﬁcation of AML.
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